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a  b  s  t  r  a  c  t
Cancer  is  a disease  characterized  by  unrestrained  cellular  proliferation.  In  order  to  sustain  growth,  can-
cer cells  undergo  a complex  metabolic  rearrangement  characterized  by  changes  in  metabolic  pathways
involved  in  energy  production  and  biosynthetic  processes.  The  relevance  of  the  metabolic  transformation
of  cancer  cells  has  been  recently  included  in  the  updated  version  of the  review  “Hallmarks  of  Cancer”,
where  dysregulation  of  cellular  metabolism  was included  as an  emerging  hallmark.  While  several  lines of
evidence  suggest  that  metabolic  rewiring  is  orchestrated  by the  concerted  action  of  oncogenes  and  tumor
suppressor  genes,  in  some  circumstances  altered  metabolism  can  play  a  primary  role  in  oncogenesis.eywords:
ancer metabolism
itochondria
arburg
ost metabolism
ancer therapy
Recently,  mutations  of  cytosolic  and  mitochondrial  enzymes  involved  in key  metabolic  pathways  have
been  associated  with  hereditary  and  sporadic  forms  of  cancer.  Together,  these  results  demonstrate  that
aberrant  metabolism,  once  seen  just  as an  epiphenomenon  of oncogenic  reprogramming,  plays a key role
in oncogenesis  with  the  power  to control  both  genetic  and  epigenetic  events  in cells.  In  this  review,  we
∗ Corresponding author at: Duke Molecular Physiology Institute, 300 N. Duke Street, Durham, NC 27701, USA.
E-mail address: matthew.hirschey@duke.edu (M.D. Hirschey).
1 Equal contribution; authors listed alphabetically.
2 The complete list of contributing authors on the target validation team are listed alphabetically in the acknowledgements.
ttp://dx.doi.org/10.1016/j.semcancer.2015.10.002
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discuss  the  relationship  between  metabolism  and cancer,  as  part  of a larger  effort  to  identify  a broad-
spectrum of therapeutic  approaches.  We  focus  on  major  alterations  in nutrient  metabolism  and  the
emerging  link  between  metabolism  and  epigenetics.  Finally,  we  discuss  potential  strategies  to manipulate
metabolism  in cancer  and  tradeoffs  that  should  be considered.  More  research  on the  suite of  metabolic
alterations  in cancer  holds  the potential  to discover  novel  approaches  to treat it.
evier
1
l
w
s
t
b
g
a
o
a
c
o
a
o
t
p
c
p
l
t
c
t
a
i
m
m
e
c
u
F
l
b
t
2
t
W
m
o
o
w
c
w
l
t
e
a
i
W
g© 2015  Els
. Introduction
A non-profit organization called Getting to Know Cancer
aunched an initiative entitled “The Halifax Project” in 2011, which
as charged with identifying synergistic molecular targets and/or
mall molecules for each of the areas that are widely considered
o be hallmarks of cancer [1]. The rationale for this approach is
ased on the idea that cancers harbor significant genetic hetero-
eneity [2], which is often not addressed with monotherapeutic
pproaches. While efforts have been made to combine therapies to
vercome resistance, rising drug costs, significant levels of toxicity,
nd a lack of overall success have stymied efforts to effectively treat
ancer with multi-drug combinations [3].
Thus, the first aim of the Halifax Project was to produce a series
f reviews, including this review on cancer metabolism, to broadly
ssess current knowledge on the biology of cancer. The overall goal
f the Halifax Project is to identify biological targets and prospec-
ive lead compounds that could potentially be used to reach each
rioritized area, and synergistically target multiple hallmarks of
ancer. By building this rationale into the approach a priori, the
roblem of heterogeneity might be overcome. In theory, multiple
ow toxicity approaches could be experimentally combined, which
hen might lead to synergism within a given hallmark, such as can-
er metabolism. Future studies will build upon these findings and
est these hypotheses, as well as integrate these concepts into the
pproaches recommended in other hallmark areas in this special
ssue.
In this review, we first discuss the relationships between
etabolism and cancer. We  focus on major alterations in nutrient
etabolism, as well as the emerging links between metabolism and
pigenetics. Next, we discuss potential therapeutic strategies that
ould be used to manipulate metabolism in cancer cells or to manip-
late host metabolism thereby influencing cancer metabolism.
inally, we describe tradeoffs that should be considered when
everaging these approaches. Together, this information will be the
asis of significant future research to fully realize the potential of
argeting metabolism in cancer.
. Classic metabolic derangements
The first realization that metabolism is altered in cancer can
race its roots to the work of Otto Warburg. During the 1920s,
arburg found that unlike most normal tissues, cancer tissues fer-
ented glucose to lactate at high rates regardless of the presence
f oxygen [4,5]. This was in contrast to the results that Pasteur had
btained previously studying fermentation in yeast, whereby O2
as found to inhibit fermentation [6,7]. To study the metabolism of
ancer in vivo, Warburg used Jensen sarcoma cells to form tumors
ithin the abdomens of rats. By comparing arterial glucose and
actate concentrations to venous glucose and lactate concentra-
ions, Warburg was able to infer the glucose uptake and lactate
xcretion by the tumor. Whereas normal tissues took up 2–18% of
rterial glucose, tumors consumed 47–70%. Lactate was not signif-
cantly changed in blood after perfusion of normal tissues, but by
arburg’s calculations, tumors converted 66% of their consumed
lucose into lactate. Thus, Warburg surmised that tumors take up Ltd.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
much more glucose than normal tissues and convert a much larger
percentage of it to lactate [4].
Warburg’s work on respiration and fermentation in cancer cells
ultimately led him to propose that “the respiration of all cancer
cells is damaged” [8]. In fact, he reasoned that known carcinogens,
such as arsenic and hydrogen sulfide, likely worked by inhibiting
respiration. He suggested that the primary oncogenic insult was
an inability of cells to oxidize glucose carbons, and that X-rays
were carcinogenic mainly due to their effect on mitochondria [8],
which by this time had been shown to be the respiratory center of
cells.
The exact molecular mechanisms leading to altered metabolism
in cancer and the Warburg effect remain a major unsolved question;
for a review, see [9]. Subsequent studies have shown that while
changes in mitochondrial respiration are sometimes seen in cancer
cells, these alterations are not likely the driving lesion for most
cancer cells. For example, Warburg’s follow-up work suggested
that oxidative respiration was important in malignant tumors, and
reported that placing rats in 5% O2 for 40 h resulted in the death of
most cancer cells, suggesting that oxygen was  needed for viability
of those cancer cells [4]. Similarly, the work of his contemporaries
showed that oxygen consumption is intact in many cancers, thereby
decoupling the Warburg effect from defective oxygen consump-
tion [10,11]. However, oxygen consumption cannot be a direct
measurement of intact respiration, because mitochondrial cou-
pling/uncoupling influences the efficiency of oxygen consumed to
ATP produced. Nevertheless, many cancer cells display increased
glucose uptake and elevated lactate production, irrespective of
oxygen availability – also called “aerobic glycolysis” or the War-
burg effect [12], and this observation remains a hallmark of altered
metabolism in cancer cells.
3. Emerging metabolic derangements
While the mechanisms leading to the Warburg effect are
under intense investigation, the general consensus of the field
is that dysregulated metabolism and altered mitochondrial
structure–function [13] is consistently found in several cancer
cell types. These changes may  occur before, as a result of, or in
combination with, the genetic changes driving cancer, including
oncogene expression or tumor suppressor loss; for recent compre-
hensive reviews on these concepts, see [14,15]. For example, one
well-studied link between oncogenesis and glucose metabolism is
the phosphoinositide 3-kinase (PI3K) signaling pathway. Activat-
ing mutations in PI3K or overexpression of the AKT oncogenes,
which lie downstream of PI3K, can induce high rates of aerobic gly-
colysis in non-transformed cells. This occurs in part by increasing
expression and localization of the high-affinity glucose transporter,
GLUT1, on the plasma membrane [16,17]. In addition, activa-
tion of the PI3K pathway can accelerate flux through glycolysis
by increasing the activity of hexokinase-2, phosphfructokinase-
1 (PFK1), or phosphofructokinase-2 (PFK-2) [18–20]. The tumor
suppressor p53, which has a well described role in DNA dam-
age sensing, cell cycle control, and control of apoptosis, is also
able to oppose the Warburg effect by stimulating respiration and
reducing glycolytic flux [21–23]. Thus, loss of p53 in cancer cells
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Table  1
Prioritized pathways to target cancer metabolism.
Target Known pathways Predicted manipulation
Hexokinase 2 (HK2) Glucose metabolism Reduce glucose uptake
and metabolism
6-Phosphofructo-2-
Kinase/Fructose-2,6-
Biphosphatase 3
(PFKFB3)
Glucose metabolism Reduce glycolysis
Pyruvate kinase isoform
M2 (PKM2)
Glucose metabolism Activate pyruvate
oxidation
Glutaminolysis Amino acid
metabolism
Inhibit glutamine
anaplerosis
Reductive carboxylation Amino acid
metabolism
Inhibit reductive
carboxylation
O-GlcNAcylation Epigenetics Unknown
Methylation/one-carbon
metabolism
Epigenetics Unknown
Acetylation/sirtuin
deacylases (SIRTs)
Epigenetics Unknown
Oncometabolites Epigenetics Inhibit oncometabolite
formation and
signaling
Lactate Glucose metabolism Inhibit use of lactate as
a fuel
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ells.
Given the inextricable relationship between oncogenes, tumor
uppressors, and the regulation of glycolysis, metabolic alter-
tions including the Warburg effect could provide a selective
dvantage to rapidly proliferating cells [24]. Although fermen-
ation produces almost 20 times less adenosine 5′-triphosphate
ATP) per glucose molecule than oxidative glucose metabolism,
TP is never limiting in dividing cells [24,25]. Instead, prolif-
rating cells require macromolecular precursors and reducing
ower in the form of reduced nicotinamide adenine dinucleo-
ide phosphate (NADPH) to synthesize new biomass. Therefore,
ne possible advantage of the Warburg effect is that high flux
hrough glycolysis allows for more efficient use of glycolytic
ntermediates for NADPH production and biosynthetic path-
ays including lipid synthesis, nucleotide synthesis, and amino
cid synthesis, which would be permissive for rapid cellular
roliferation.
Although glucose metabolism is important for proliferating
ells, other nutrient sources contribute as well. TCA cycle inter-
ediates are required for biosynthetic processes, including the
eneration of citrate for lipid synthesis and aspartate for nucleotide
ynthesis. When these intermediates are removed from the TCA
ycle, they must be replenished in a process known as anaplero-
is. Glutamine has been shown to be a key contributor to
naplerotic flux in many cancer cells [26,27]. Glutamine car-
on entry into the TCA cycle supports both ATP generation and
iosynthesis, and a wide variety of cancer cell types are sensi-
ive to glutamine withdrawal [28,29]. Catabolism of extracellular
rotein can also contribute carbon to the TCA cycle [30], and
ipids are scavenged to support proliferation of some cancer cell
ypes [31].
Collectively, metabolic shifts that enable the generation
f biosynthetic precursors are a key feature in cancer ini-
iation, development, and/or growth. Below, we discuss how
lterations in key metabolic pathways contribute to biomass gen-
ration (Table 1). We  discuss some prioritized targets within
hese pathways, their therapeutic potential, and strategies to
anipulate metabolism for the prevention or treatment of
ancer.er Biology 35 (2015) S129–S150 S131
4. Glucose metabolism
4.1. Hexokinase 2 (HK2)
Regulation of glycolysis is exerted by the three important
kinases that catalyze discrete phosphorylation reactions (Fig. 1).
Hexokinases are a family of enzymes that catalyze the first phos-
phorylation of glucose to glucose-6-phosphate. Early work on a
highly malignant AS-30D hepatoma cell line showed that one
isozyme of hexokinase was uniquely bound to the outer mitochon-
drial membrane [32,33], which was  later identified as Hexokinase
2 (HK2) [34].
In a series of experiments in this system, removal of malig-
nant tumor mitochondria containing bound hexokinase from the
cytoplasm by centrifugation markedly decreased the rate of glycol-
ysis. Then, when tumor mitochondria containing bound hexokinase
were added back to the tumor cytosol, the original glycolytic
capacity of the cytoplasm was restored. Finally, when solubilized
hexokinase alone was added to the liver cytosol, it markedly
enhanced the glycolytic rate [34]. Therefore, HK2 could be a
major contributor to high glycolysis and lactate production even
in the presence of oxygen. One mechanism by which HK2 binds
to mitochondria is via the outer membrane protein known as the
voltage-dependent anion channel VDAC [35]. This binding interac-
tion facilitates the immortalization of cancer cells [36,37].
To identify compounds that could selectively inhibit the two
main energy-producing pathways (glycolysis and mitochondrial
oxidative phosphorylation), a limited screen was  performed in can-
cer cells. The small molecule 3-bromopyruvate (3BP) was identified
as an inhibitor of glycolysis and also as an inhibitor of mitochon-
drial energy production, which could be explained by inhibiting
HK2 [38]. Follow-up work showed that 3BP has potent anticancer
activity and has the capacity to eradicate cancers in different
animal models [39]. Furthermore, 3BP was  recently tested in a
single human case study and showed promising results [40,41].
Future work will be directed at the role of other HK isoforms in
cancer, as well as the specificity of 3BP toward HK2. However,
these early studies are one proof-of-principle that targeting energy
metabolism of cancer cells can be an effective therapeutic approach.
4.2. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
(PFKFB3)
Another gluco-regulatory kinase is phosphofructokinase (PFK),
which catalyzes the phosphorylation of fructose-6-phosphate to
fructose-1,6-bisphosphate (Fig. 1). PFK is regulated by several
metabolites, including inhibition by high concentrations of ATP
and activation by fructose 2,6-bisphosphate. Early studies indi-
cated that phosphofructokinase activity correlated with the growth
rate of Morris hepatomas transplanted in rats and also correlated
with lactate production by slices of those tissues [42]. Those obser-
vations suggested that inhibition of phosphofructokinase activity
represented a logical target for inhibition of malignant tumor
growth. With the discovery that fructose 2,6-bisphosphate is an
activator of phosphofructokinase 1 [43], the enzyme activity cat-
alyzing the formation of fructose 2,6-bisphosphate became an
alternative target for the inhibition of glycolysis and cancer growth.
Steady state levels of fructose 2,6-bisphosphate are regulated by
bifunctional enzymes that have both phosphofructo-2-kinase and
fructose-2,6-bisphosphatase (PFKFBs). Of these enzymes, PFKFB3
has the highest phosphofructo-2-kinase activity [44]. Interestingly,
PFKFB3 expression, but not other PFKFBs, is markedly elevated in
multiple aggressive primary cancers, including colon, breast, ovar-
ian and thyroid carcinomas [45].
The role of PFKFB3 in the regulation of glucose metabolism in
cancer cells has been reviewed previously [46]. An early indication
S132 M.D. Hirschey et al. / Seminars in Cancer Biology 35 (2015) S129–S150
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ingle  bonds, thin; double bonds, bold.
hat PFKFB3 might be a regulatory enzyme was the identification of
ultiple copies of the AUUUA instability motif in its 3′ untranslated
egion [44]. Expression of the PFKFB3 gene is induced by hypoxia
hrough hypoxia-inducible factor-1 [47]. Low pH, a common
eature in malignant tumors, is another factor that results in upre-
ulation of PFKFB3. This may  be mediated through the metabolic
tress sensor AMP-activated protein kinase (AMPK) resulting in an
ncrease in serine phosphorylation [48]. In breast cancer cells, syn-
hetic progestins activate PFKFB3 isoenzyme phosphorylation and a
ong-term sustained action due to increased PFKFB3 protein levels.: carbon, gray; oxygen, blue; phosphate, yellow; adenosine, A; NAD+/NADH, orange;
An immediate early response occurs through the ERK/RSK pathway
leading to phosphorylation on S461 followed by activation of tran-
scription via cis-acting sequences on the PFKFB3 promoter [49]. In
myeloproliferative neoplasms, PFKFB3 expression was  upregulated
via active JAK2 and STAT5 [50], suggesting that specific inhibitors
of PFKFB3 might inhibit JAK2/STAT5-dependent malignancies.Levels of PFKFB3 are regulated by ubiquitinylation during the
cell cycle. PFKFB3 accumulates in mid  to late G1 and breakdown
in S phase occurs specifically via a distinct S273 residue within
the conserved recognition site for SCF-beta-TrCP [51]. The activity
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f PFKFB3 is short lasting, coinciding with a peak in glycolysis in
id  to late G1 in contrast to glutamine metabolism, which remains
igh throughout S phase [52]. Glycolysis is characteristically asso-
iated with cytosolic fractions of cells but PFKFB3 has a nuclear
ocalization signal. Furthermore, nuclear localization of PFKFB3 was
ssociated with increased proliferation by increased expression of
yclin-dependent kinases and decreased expression of the cell cycle
nhibitor p27 [53]. This brings to mind the more recent observation
ith the pyruvate kinase isoenzyme PKM2 (described below) that
as been shown to have potential transcription regulatory action
n addition to its role in glycolysis [54]. Therefore, a dual func-
ion may  be associated with some regulatory enzymes involved
n glycolysis.
Molecular modeling studies were the basis for the identification
f the first published report of a small molecule inhibitor of PFKFB3
55]. This molecule, 3-(3-pyridinyl)-1-(4-pyridnyl)-2-propen-1-
ne known as 3PO became commercially available through
albiochem, EMD  Millipore in 2013. 3PO was shown to suppress
lucose uptake and glycolytic flux and was selectively cytostatic to
as-transformed human bronchial epithelial cells relative to nor-
al  cells. Growth of human erythroleukemia cells was inhibited
y 3PO [50]. Treatment of tumor-bearing mice reduced the intra-
ellular concentration of fructose 2,6-bisphosphate, glucose uptake
nd tumor growth. The observation that 3PO suppresses T-cell acti-
ation indicates a potential use for small molecule inhibitors of
FKFB3 in the treatment of autoimmune conditions but might be
roblematic in combination treatments with immunosuppressive
ancer chemotherapeutic agents [56]. A more potent derivative of
PO designated PFK15 has been identified and a phase I clinical trial
s planned [57].
.3. Pyruvate kinase isoform M2  (PKM2)
Pyruvate kinase (PK) catalyzes the final rate-limiting step in
lycolysis (Fig. 1), transferring a phosphate group from phospho-
nolpyruvate (PEP) to ADP and thereby generating pyruvate and
TP [58]. Humans have four PK enzymes: PKR is restricted to eryth-
ocytes; PKL is found predominantly in liver and kidney; PKM1 is
xpressed in differentiated somatic cells (e.g. muscle and brain) and
KM2 is found in fetal tissues and proliferating cells. In cancer cells,
xpression of PKM2 is up-regulated such that it becomes the most
redominant PK isoform [59]. Accumulating evidence suggests that
KM2 expression is elevated in cancer cells, as its enzymatic activ-
ty can be regulated by various metabolic and signaling inputs
24,60,61]. PKM2 influences the fate of glucose carbons (Fig. 1).
n general, PKM2 activity is low in proliferating cells, which cre-
tes a bottleneck at the terminal step in glycolysis, which results
n elevated concentrations of upstream glycolytic metabolites. As
 consequence, such intermediates are available for the biosyn-
hetic reactions that branch off of glycolysis, thereby increasing the
eneration of cellular building blocks needed for proliferation [24].
Current models describing the function of PKM2 in cellu-
ar proliferation focus mainly on mechanisms that regulate its
yruvate-generating activity as a cytoplasmic component of gly-
olysis [61,62]. However, recent studies have provided evidence
or activities of PKM2 that extend beyond this canonical role.
amely, several nuclear activities for PKM2, and mechanisms that
nable the shuttling of PKM2 into the nucleus, have now been
escribed [54,63–70]. Nuclear activity promotes tumor growth
hrough the direct transcriptional activation of genes involved in
ancer metabolism, including PKM2 itself and the RNA splicing fac-
ors that repress PKM1 [54,65,68]. In this way, PKM2 acts in a feed
orward loop to promote both its nuclear activities and its metabolic
ole in cancer metabolism. Ongoing studies seek to examine the
elative contributions of these two functions in oncogensis and
rowth.er Biology 35 (2015) S129–S150 S133
The central principle presented above asserts that inhibiting PK
activity facilitates proliferation. This can be achieved through the
expression of the less active and ‘regulatable’ PK enzyme, PKM2.
Alternatively, PKM2 might be upregulated to eliminate PKM1
expression; PKM1 is a constitutively active enzyme, which reduces
the generation of carbon for anabolic reactions and facilitates the
generation of ATP in the mitochondria. Recent support for this line
of thinking comes from the observation that PKM2 is not required
for tumor maintenance, where short hairpin (sh)RNA-mediated
depletion does not affect tumor growth [71]. Furthermore, genetic
experiments, in which the PKM2-specific exon was deleted in a
mouse model of breast cancer using Cre-lox technology, demon-
strated that the absence of PKM2 increased oncogenesis and
negatively affected survival. Strikingly, these tumors showed no
tissue-specific PK expression. They did, however, still produce lac-
tate from glucose, suggesting that alternative and non-canonical
methods of pyruvate generation were functioning [72]. Collec-
tively, these experiments demonstrate that PKM2 is not required
for oncogenesis or growth, and support for the concept that cancer
cells have a growth advantage by removing PKM1.
Despite potential mechanistic differences between these two
models on the role of PK in cellular proliferation, they converge on
a common point: constitutive PK activity is detrimental for prolif-
eration. Consistent with this concept, the first study to examine
the activity of PK directly in an isogenic context demonstrated
that cancer cell lines engineered to express PKM1 produce less
lactate, consume more oxygen and are less tumorigenic in nude
mouse xenografts than those expressing PKM2 [73]. Importantly,
these results demonstrated that less PK activity provided a selective
growth advantage for cancer cells in vivo.
From a therapeutic standpoint, activation of PK may  serve as
a promising strategy to slow cancer growth. Indeed, numerous
research teams in the public and private sectors have recently
developed drug-like small molecule activators of PKM2 that make
it behave more like PKM1 [74–79]. Studies using such compounds
have shown that activation of PKM2 results in decreased accumu-
lation of biosynthetic carbon building blocks and reduced cancer
growth [74]. Interestingly, all compounds described thus far share
a high degree of structural similarity and bind at the same interface
in the PKM2 multimer. The small molecule activator binding pocket
is distinct from the fructose bisphosphate (FBP) binding pocket,
where PKM2 activators overcome negative regulation by phospho-
tyrosine peptides. Together, these two  activities enable compounds
to overcome mechanisms that negatively regulate PKM2.
Several of the compounds described above have been inves-
tigated in animal models [74,75]. In one study, a compound
called TEPP-46 activated PKM2 and impaired tumor seeding and
growth. Subsequent metabolic analyses support the hypothesis
that impaired anabolic metabolism is responsible for the growth
inhibition. Future studies are now aimed at exploring the use of
these agents in combination with cytotoxic chemotherapies that
generate oxidative stress. Support for this concept comes from the
observation that activating PKM2 impairs the metabolic control
of redox – specifically the generation of reducing equivalents in
the form of NADPH and GSH [80] – which sensitizes cancer cells
to further oxidative stress. Finally, PKM2 activators may  prove to
be doubly effective, as multimer formation prevents the nuclear
translocation of PKM2 and thus its activity as a protein kinase and
activator of gene expression [67].
5. Amino acid metabolismIn addition to the well-established role for altered glucose
metabolism in cancer, recent research highlights the involve-
ment of amino acid metabolism in cancer, especially glutamine.
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n proliferating cells, the tricarboxylic acid (TCA) cycle functions
s a source of precursors for macromolecular synthesis in addition
o generating reducing equivalents for oxidative phosphorylation
81]. Citrate, for example, is both the canonical entry point of the
CA cycle and a precursor for the acetyl-CoA used in fatty acid/sterol
ynthesis and acetylation reactions. Normally, the withdrawal of
itrate to supply these other pathways is matched by an influx of
arbon into the cycle to yield oxaloacetate, refilling the pools of TCA
ycle intermediates and maintaining function of the cycle during
rowth [26].
In culture, many cancer cells meet their anaplerotic demand
hrough the oxidative metabolism of glutamine to oxaloacetate
Fig. 2) [26]. Glutamine is an advantageous anaplerotic precur-
or because its conversion to -ketoglutarate (-KG) has the
otential to disperse nitrogen to hexosamines, nucleotides, and
on-essential amino acids, all of which are required for growth. Fur-
hermore, oxidative metabolism of -KG to oxaloacetate produces
educing equivalents that can be used to generate energy [82].
lternative anaplerotic pathways, such as pyruvate carboxylation,
lso produce oxaloacetate but do not satisfy these other demands,
ositioning glutamine as a key player in mitochondrial metabolism.
.1. Glutaminolysis
Glutamine is a non-essential amino acid with an amine func-
ional group and is the most abundant amino acid in circulation
83]. Glutamine supplies nitrogen for nucleobase synthesis and car-
on for the TCA cycle, lipid synthesis and nucleotide synthesis [84].
lutamine is involved in both anabolic and catabolic processes.
he catabolism of glutamine is called glutaminolysis, which can
e converted into glutamate, aspartate, CO2, pyruvate, lactate, ala-
ine and citrate. The first step of glutaminolysis is the conversion of
lutamine to glutamate and ammonia via glutaminase (GLS). After
lutamine is converted into glutamate, the glutamate is oxidized
nto -KG. This most often occurs through the enzyme glutamate
ehydrogenase (GLDH), concomitant with the generation of mito-
hondrial NADH or NADPH and ammonia [85]. This is the first
nergy-yielding step in glutaminolysis and is the link to the TCA
ycle (Fig. 2).
While glutaminolysis is a normal process for many cells, such
s lymphocytes and adipocytes, many cancer cells have elevated
lutamine flux. In cell culture, human glioma and HeLa cells were
ound to be completely dependent upon glutamine for their sur-
ival. The cells died in the absence of glutamine, despite being
n glucose-rich media, which is now known as the complete
ependence on glutamine for cell survival (a.k.a. glutamine addic-
ion) [28,86]. Interestingly, not all cancer cells exhibit glutamine
ddiction. While the complete molecular mechanism of glutamine
ddiction is not known, several oncogenic mutations or alterations
ave been found to explain glutamine-dependence in cancers. For
xample, Myc  is able to increase glutamine metabolism by upregu-
ating GLS expression, which leads to glutamate entry into the TCA
ycle as -KG [87].
The ability to use exogenous glutamine is enhanced by the
pregulation of glutamine transporters [88]. For example, one
tudy found the increase in glutaminolysis was so profound that
ancer cells accumulated more glutamine than was necessary to
eet the energy and anabolic requirements of the cell; excess
lutamine-derived carbon was secreted from the cells in the form
f lactate or, to a lesser extent, alanine [28]. Further evidence sug-
ests that overexpression of Myc  is enough to induce glutamine
ddiction, due to the fact that this mutation causes the metabolism
f the mitochondria to be altered in such a manner as to rely
n glutamine despite available glucose [28]. Interestingly, these
lutamine-addicted cells were found to be keenly sensitive to elec-
ron transport chain inhibitors. This observation could indicate thater Biology 35 (2015) S129–S150
either the potential energy in glutamine is being used in the pro-
duction of ATP [89] or that mitochondrial glutamate uptake by the
glutamate/aspartate mitochondrial transporter requires a proton-
motive force.
In human pancreatic ductal adenocarcinoma (PDAC), the
oncogene KRAS contributed to glutamine dependency by using
glutamine-derived aspartate to produce oxaloacetate via aspar-
tate transaminase (GOT1) in the cytoplasm. Oxaloacetate was in
turn converted into malate and then pyruvate to maintain a high
NADPH/NADP+ ratio for redox homeostasis. Therefore, disrupting
these reactions, and ultimately glutamine metabolism, led to sup-
pression of PDAC growth in vitro and in vivo [90].
In a recent study, the use of nuclear magnetic resonance
(NMR) spectroscopy and mass spectrometry (MS), as well as sta-
ble isotope-resolved metabolomics, allowed the fate of 13C and 15N
from labeled glutamine in B lymphoma cells to be traced under aer-
obic and hypoxic glucose-deprived conditions [91]. In this study,
glutamine is the fuel that drives the TCA cycle, which is com-
pletely independent of the glucose supply. This reprogramming of
the TCA cycle is particularly advantageous to cancer cells under
glucose-deprived and/or hypoxic conditions. Where glucose is pref-
erentially converted to lactate under hypoxic conditions, glutamine
metabolism serves to sustain ATP production and redox homeosta-
sis in order to support cancer cell growth and survival. This implies
that even hypoxic cancer cells can oxidize glutamine through the
TCA cycle, and in the absence of glucose, glutamine metabolism
alone can sustain the TCA cycle and thereby meet the anapleurotic
and energetic demands of the proliferating cancer cells.
Supporting this idea, Myc-transformed cells were found to rely
on a means of -KG synthesis other than that involving GLDH.
Aspartate and alanine transaminases reversibly convert glutamate
into -KG, along with oxaloacetate to aspartate or pyruvate to
alanine, respectively (Fig. 2). These reactions occur despite the pres-
ence of GLDH in the mitochondria of cancer cells, which catalyzes
the direct conversion of glutamate to -KG [92]. This is espe-
cially important considering it was found that Myc-transformed
breast cancer cells undergo apoptosis when aspartate transami-
nase is inhibited. This implies that this cancer is heavily reliant upon
transaminase reactions to produce -KG [93,94].
Due to the central nature of glutaminolysis in many cancers, it
is becoming an increasingly prominent target in cancer therapy.
One of the early strategies to suppress glutamine metabolism was
to reduce the amount of available glutamine by using glutamine
analogs. Compounds such as 6-diazo-5-oxo-l-norleucine (DON)
and acivicin showed cytotoxic effects against several malignant
tumors types, including leukemia and colorectal cancers; however
these analogs are no longer clinically available due to patient tox-
icity [95].
More recent strategies have focused on targeting the enzymes
of glutamine metabolism. For example, GLS is a potential target
for the inhibition of glutaminolysis in cancer cells. The kidney iso-
form, GLS1, is found in many malignant tumors [96] while the liver
isoform, GLS2, is less often expressed in cancers. The compound bis-
2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide (BPTES)
has been shown to inhibit growth of a variety of cancers in mouse
models and in cell culture, including B lymphoma, which allosteri-
cally inhibits GLS1 by altering the conformation of the enzyme [97].
The effect is enhanced under hypoxic conditions, often inducing
cancer cell death [91].
GLDH is another potential target of glutaminolysis, which when
knocked-down by siRNA resulted in a marked decrease in the pro-
liferation of glioblastoma cells that were glutamine dependent [98].
Green tea polyphenols, hexachlorophene, GW5074, and bithionol
may  inhibit GLDH function. These inhibitors work by restricting
enzyme movement, either by forming rings around the enzyme
or wedging between the enzyme’s subunits. Currently, green tea
M.D. Hirschey et al. / Seminars in Cancer Biology 35 (2015) S129–S150 S135
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olyphenols have been shown to inhibit lung, colon, and prostate
denocarcinoma growth in xenograft models [99]. These com-
ounds also had significant effects on glioblastoma, colon, lung and
rostate adenocarcinoma cell proliferation [100].
Another strategy to inhibit glutaminolysis is to target alanine
ransaminase through l-cycloserine [101] or aspartate transam-
nase through amino oxyacetate [93] which nearly halted the
rowth of breast cancer xenografts in mice. Similarly, aspartate
ransaminase knockdown in pancreatic cancer is also dramat-
cally growth inhibitory in vitro and in vivo and leads to a
rofound disruption of redox homeostasis [90]. In both of these
ases, little to no toxicity was observed with transaminase inhibi-
ion in non-neoplastic cells. These studies suggest that aspartate
minotransferase is a promising cancer target. Finally, given that
nhibition of aspartate transaminase also leads to a disruption of
edox homeostasis, such inhibition may  synergize with therapies
hat increase reactive oxygen species (ROS), such as chemotherapy
nd radiation [102].
.2. Reductive carboxylationNot all cancer cells have the ability to perform glutaminoly-
is. Hypoxia limits the oxidative capacity of the TCA cycle, and
n particular suppresses production of acetyl-CoA from glucose
ia pyruvate dehydrogenase (PDH) [103,104]. Furthermore, someown in bold. Reductive direction of the TCA cycle shown with blue arrows. Color
coenzyme A, light gray; NAD+/NADH, orange; NADP+/NADPH, brown; FAD/FADH2,
cancer cells contain severe mutations in TCA cycle enzymes (suc-
cinate dehydrogenase, fumarate hydratase) or in components of
the electron transport chain that prevent efficient production of
oxaloacetate from glutamine [105]. Yet, both hypoxic cells and
cells with defective mitochondria require glutamine for growth
[106–108]. To address this paradox, metabolic labeling experi-
ments were performed using 13C, and revealed that these cells
metabolize glutamine through an unusual pathway characterized
by “reversal” of isocitrate dehydrogenase (IDH) enzyme activity
(Fig. 2, blue arrows) [106,107,109,110]. IDH typically acts as an
oxidative decarboxylase, converting isocitrate to -KG and CO2
in the presence of an electron acceptor. Indeed, IDH3, the mito-
chondrial NAD+-dependent IDH isoform, functions exclusively in
this manner. However, the two  other mammalian IDH isoforms,
IDH1 and IDH2, use NADP+/NADPH as cofactors, and can act
either as oxidative decarboxylases or reductive carboxylases. In
the latter reaction, -KG is carboxylated to produce isocitrate, con-
verting NADPH to NADP+. Isocitrate is readily converted to citrate,
which can then be cleaved to produce acetyl-CoA. Under condi-
tions of reductive carboxylation, glutamine becomes the major
source of acetyl-CoA for fatty acid synthesis, greatly decreasing
the need to produce acetyl-CoA from glucose. Furthermore, cit-
rate cleavage yields oxaloacetate, which is converted to other
4-carbon intermediates, meaning that essentially the entire cellu-
lar pool of TCA cycle intermediates can be derived from reductive
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arboxylation, in reverse order to their conventional route of pro-
uction (Fig. 2).
Reductive carboxylation had previously been observed as a
inor source of isocitrate and citrate in a number of non-
ransformed mammalian tissues [111–114]. Its importance in
ancer cell biology is related to its ability to serve as the major
ource of citrate and acetyl-CoA when cellular circumstances
onspire to inactivate pathways that normally produce these
etabolites, including hypoxia and genetic reprogramming of
itochondrial metabolism. For example, the Von Hippel–Lindau
VHL) tumor suppressor normally functions in the oxygen-
ependent degradation of the alpha subunits of the hypoxia
nducible factor (HIF) transcriptional activators. Thus, in cells
xpressing VHL, oxygen facilitates the degradation of HIF1 and
IF2 so that HIF target genes are not expressed. In contrast, in
alignant tumor cells lacking VHL, HIF target genes are expressed
egardless of oxygen availability. These genes, which include glu-
ose transporters and glycolytic enzymes, are part of the metabolic
daptation to hypoxia. Importantly, hypoxia stimulates the expres-
ion of PDH kinase-1 (PDK1), which phosphorylates and inactivates
he PDH complex, impairing its ability to provide acetyl-CoA and
itrate from glucose [103,104]. Cancer cells lacking VHL produce
 substantial fraction of citrate and fatty acids using glutamine-
ependent reductive carboxylation in culture, and a small but
etectable fraction of citrate in vivo [115]. Heterologous expression
f wild-type Vhl, or silencing of PDK-1, partially reverts metabolism
o a phenotype in which citrate and fatty acids are produced from
lucose/PDH [115].
Regulation of reductive carboxylation is an area of active inves-
igation. Importantly, the pathway is stimulated by mutations in
he electron transport chain that impair recycling of mitochon-
rial NADH to NAD+, but importantly NADPH is the cofactor for
eductive carboxylation. This suggested a model in which a low
AD+/NADH ratio in mitochondria provides a source of reduc-
ng equivalents which are transmitted to NADPH by nicotinamide
ucleotide transhydrogenase (NNT) [107]. NNT is an inner mito-
hondrial membrane protein that uses the electrochemical proton
radient to transfer reducing equivalents from NADH to NADPH
116]. Silencing NNT expression in SkMel5 melanoma cells reduced
he contribution of glutamine carbon to TCA cycle intermediates
hrough both oxidative and reductive metabolism, and decreased
he rate of growth of SkMel5-derived subcutaneous xenografts
117]. In VHL-deficient 786-O renal carcinoma cells, which produce
 large fraction of citrate via reductive carboxylation, NNT silencing
ignificantly suppressed reductive glutamine metabolism. These
ndings suggested that NADPH produced by NNT is required for
eductive carboxylation in VHL-deficient cells.
Reductive carboxylation is also regulated by changes in the
bundance of TCA cycle metabolites. Citrate levels tend to be low
n cells with active reductive carboxylation, and maneuvers to sup-
ress formation of citrate from glucose enhance the fraction of
itrate derived from reductive carboxylation [106,107,109,115]. In
ontrast, supplying cells with exogenous acetate or citrate increases
he ratio of citrate/-KG while reducing the overall contribution of
eductive carboxylation to TCA cycle metabolism [115].
Compartmentalization of the reductive carboxylation reaction is
ot well understood. IDH1 is cytosolic while IDH2 is localized to the
itochondria, and data suggest that each isoform can participate in
eductive carboxylation. IDH2 was found to be the crucial isoform
or reductive carboxylation in hypoxic glioma cells [109], whereas
ther cell lines required IDH1 under hypoxia [106]. Genetic sup-
ression of pyruvate dehydrogenase in lung cancer cells is sufficient
o induce a net flux of reductive carboxylation, and under these
ircumstances the flux is completely dependent on IDH1 [118].
n cells with mutations in the electron transport chain, silencing
ither isoform reduced activity of the pathway, and silencing bother Biology 35 (2015) S129–S150
together had a maximal effect [107]. The involvement of NNT as a
source of NADPH argues for mitochondrial localization of the reduc-
tive carboxylation reaction, at least in those cells that require NNT
expression to maintain citrate levels. However, cytosolic sources of
NADPH, including the oxidative branch of the pentose phosphate
pathway, may  play a more prominent role in cells where IDH1 cat-
alyzes reductive carboxylation. Presumably, the choice of isoform is
also related to localization of an available source of the substrate -
KG, meaning that compartmentalization of glutamine metabolism
could add another dimension to regulation of this pathway.
6. Lipid metabolism
Cancers may  use a wide variety of substrates and substrate
sources to meet their catabolic and anabolic needs, including
internally and externally derived fatty acids (FAs). Indeed, FAs
are essential for cellular proliferation. In particular, FAs are used
as cellular building blocks for lipid membrane synthesis, for
energy storage and production, as well as for cellular signaling.
Thus, limiting abundance of FAs could be a therapeutic strategy
against cancer. Limiting cellular FAs could be achieved by: blocking
synthesis (lipogenesis), increasing breakdown (oxidation), reduc-
ing availability from storage (lipolysis), or by increasing FA flux
toward storage (re-esterification); these distinct strategies have
been considered as chemotherapeutic strategies recently [119].
As with other metabolic shifts in cancer, characterizing the state
of lipid metabolism in unique cancer types and cells lines is an
important first step. Indeed, successful chemotherapeutic strate-
gies will require understanding the specific abnormalities in lipid
metabolism for a given cancer type. Targeting lipid metabolism in
cancer is an emerging idea that warrants further investigation.
7. Epigenetics and oncometabolites
In addition to alterations in metabolism, metabolic repro-
gramming mediated by specific oncogenes and tumor suppressors
can impact dynamic regulation of chromatin via post-translational
modifications. Indeed, increasing evidence indicates that altered
metabolism can also lead to changes in nutrient-sensitive post-
translational modifications. These chemical modifications, such
as O-GlcNAcylation, methylation, and acetylation, can impact the
activities of metabolic enzymes, signaling components, trans-
criptional regulators, and chromatin-associated proteins such as
histones [120–124]. Furthermore, oncometabolites, such as 2-
hydroxyglutarate (2-HG), can have profound consequences on
the regulation of chromatin organization, gene expression, and
genome integrity. Improved understanding of the links between
metabolism and epigenetics is expected to have important thera-
peutic implications, and intense efforts are currently geared toward
targeting both altered metabolism and epigenetics [125,126].
7.1. O-GlcNAcylation
The hexosamine biosynthetic pathway (HBP), a branch
of metabolism that diverges from glycolysis at fructose-6-
phosphate, generates uridine diphosphate N-acetylglucosamine
(UDP-GlcNAc), a key donor substrate for glycosylation reac-
tions, including the O-GlcNAc modification, which is mediated by
O-GlcNAc transferase (OGT) [122,127,128]. O-GlcNAcylation is gen-
erally elevated in cancer cells and has been linked to malignant
tumor growth through direct modification of phosphofructoki-
nase (PFK1) and indirect regulation of FoxM1 [129–131]. All four
histones (H2A, H2B, H3, and H4) are modified by O-GlcNAc,
which is dynamically regulated in response to nutrient availabil-
ity [132–134]. O-GlcNAcylation of histone H3 on Ser10 is cell cycle
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egulated and suppresses mitosis-specific H3 phosphorylation
135], whereas H2B Ser112 O-GlcNAcylation facilitates monoubiq-
itylation of Lys120 of histone H2B, a mark associated with active
ranscription, indicating a role for O-GlcNAc in gene regulation
hrough chromatin modification [134]. OGT can also associate with
en–Eleven-translocation (TET) family 5-methylcytosine hydroxy-
ases and participate in TET-mediated gene regulation [136–139].
hether cancer cells exhibit altered histone O-GlcNAcylation pat-
erns due to metabolic alterations is not yet clear. Notably, TET2
unction is frequently disrupted in hematopoietic malignancies
140–142], and future studies will determine whether changes
n histone O-GlcNAcylation participate in cancer development in
hese cases.
.2. Methylation
Alterations in histone and DNA methylation are widely observed
n cancer. Many cancer types display global DNA hypomethylation
ompared with normal tissue, while genes regulating cell-cycle and
NA damage response are frequently found to be hypermethy-
ated, and thus silenced [143]. Histone and DNA methyltransferases
tilize the methyl donor S-adenosyl methionine (SAM), which is
ynthesized from methionine and ATP. Hence, SAM availability for
ethylation reactions may  be sensitive to levels of methionine
aken up from the environment or synthesized through one-carbon
etabolism pathways, discussed in more detail below. In yeast,
AM can serve as a sensor of amino acid availability, inhibiting
utophagy and promoting growth [144]. While transformed cells
equire growth medium supplemented with methionine [145],
nowledge of how cancer cells use methionine to regulate his-
one and DNA methylation is still limited. Notably, the enzyme
icotinamide N-methyltransferase (NNMT), which depletes SAM
y catalyzing the transfer of SAM’s methyl group to nicotinamide,
s frequently overexpressed in human cancers. A recent study
emonstrated that NNMT levels impact methylation in cancer cells,
ith NNMT overexpression associated with reduced levels of SAM
nd histone methylation [146]. Interestingly, metabolic regulation
f SAM production has also been implicated in modulating his-
one methylation levels and maintaining pluripotency in mouse
mbryonic stem cells [147]. In addition to overall cellular lev-
ls of SAM, localized pools of SAM may  provide an additional
ayer of metabolic control. The enzyme methionine adenosyl-
ransferase (MATII), which produces SAM, has been localized
o gene promoters and implicated in gene regulation, indicating
hat enzymatic production of metabolites can be targeted to spe-
ific loci and coupled to transcriptional regulation [148]. DNA and
istone methylation levels are also controlled by rates of demethy-
ation. Metabolic control of demethylation is discussed below in
he “Oncometabolites” sub-section. Given the substantial evidence
hat DNA and histone methylation abnormalities contribute to
ancer initiation and growth, further investigation into the role
f metabolism in determining methylation changes in cancer is
eeded.
.3. Acetylation
Lysine acetylation levels are determined by the combined
ctions of lysine acetyltransferases (KATs) and deacetylases
HDACs), both of which may  be influenced by metabolic state.
istone proteins are acetylated at multiple lysines, and these
odifications are involved in chromatin-dependent processes,
ncluding gene transcription, DNA replication, and DNA damage
epair. In mammalian cells, nuclear-cytosolic acetyl-CoA, the donor
ubstrate for acetylation reactions, is generated either through
he cleavage of citrate by ATP-citrate lyase (ACLY) or directly
rom acetate by acetyl-CoA synthetases [122]. Histone acetylationer Biology 35 (2015) S129–S150 S137
can be regulated by the availability of glucose or acetyl CoA
[149–152], and in mammalian cells glucose-dependent regula-
tion of histone acetylation occurs in an ACLY-dependent manner
[149]. Reciprocally, nuclear-cytoplasmic lysine deacetylation can
be mediated by SIRT1, a member of the NAD+-dependent sir-
tuin family of lysine deacetylases [class III histone deacetylases
(HDACs)] [153,154]. NAD+ levels rise under nutrient-restricted
conditions, in part mediated by AMP-activated protein kinase
(AMPK) [155,156]. In addition, the ketone body -hydroxybutyrate
(OHB) was recently demonstrated to function as an endoge-
nous inhibitor of class I HDACs under ketogenic conditions and
influence the state of histone acetylation and gene transcription
[157].
Metabolic control of histone acetylation is likely to impact can-
cer growth, although this has not yet been directly shown. In yeast,
acetyl-CoA acts as a growth signal, promoting histone acetylation
at and expression of growth-related genes [151]. Levels of ACLY
are frequently elevated in cancer [158], although the impact of
this on overall histone acetylation is not yet known. Global his-
tone acetylation levels are highly heterogeneous among cancers,
and several studies have shown correlations with cancer recurrence
and patient survival [159–163]. Both KAT and HDAC inhibitors have
shown promise in cancer therapy [125], although mechanisms of
action remain poorly understood.
7.4. Sirtuin deacylases (SIRTs)
The sirtuins (SIRT1-7) are a class of conserved NAD+-dependent
deacylases that control cellular metabolic processes and protect
the cell against metabolic and genotoxic stresses. Not surprisingly,
altered regulation of the sirtuins is associated with many dis-
eases such as diabetes, neurodegenerative diseases, obesity, and
cancer [164]. Rapidly proliferating cancer cells require shifts in
metabolism that promote anabolic metabolism; as such, the sir-
tuins play important roles in controlling cancer development and
progression by maintaining normal cellular metabolism. Of the 7
mammalian sirtuins, SIRT1, SIRT3, SIRT4, and SIRT6 have been asso-
ciated with various types of cancer. SIRT1, SIRT3, and SIRT6 are
strong deacetylases, while the enzymatic activity of SIRT4 is less
clear but it has been shown to be a weak ADP-ribosyltransferase and
possibly a weak deacetylase [165]. SIRT1 and SIRT6 serve to mainly
deacetylate histones and transcription factors in the nucleus, while
SIRT3 and SIRT4 are mitochondrial, where they act on metabolic
proteins [166].
SIRT1 shares the most homology to Sir2 (Saccharomyces cere-
visiae), the first sirtuin identified, and has been shown to increase
lifespan and protect against age-related diseases. The main targets
of SIRT1 are the transcription factor peroxisome proliferator-
activated receptor gamma  coactivator 1-alpha (PGC1), the FOXO
family of transcription factors, and the tumor suppressor p53 [167].
Studies have found that SIRT1 expression is elevated in certain can-
cers and repressed in others, making the role of SIRT1 in cancer
difficult to define [168]. It seems as though the main confusion
underlying the role of SIRT1 in cancer is the complexity behind
the SIRT1-mediated inhibitory deacetylation of p53. SIRT1 expres-
sion is also positively regulated by p53 in an apparent negative
feedback loop where loss of p53 reduces SIRT1 expression, lead-
ing to an increase in p53 activity [169]. SIRT1 has been described
as a tumor suppressor that promotes the DNA damage response,
and SIRT1+/− p53+/− mice develop cancer in a variety of tissues,
particularly sarcomas. Furthermore, SIRT1 overexpressing mice are
more metabolically efficient, resistant to diabetes, and no cancer
phenotype has been reported in these mice [170]. SIRT1 expres-
sion is reduced in various human cancers, particularly breast cancer
and hepatocellular carcinoma [171]. Activation of SIRT1 has already
proven beneficial in BRCA1-associated breast cancers as treatment
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ith resveratrol activated SIRT1 and inhibited cell proliferation
n vitro and tumor growth in vivo [172]. It seems as though
ctivation of SIRT1 may  have therapeutic potential in certain can-
ers in order to normalize cellular metabolism and improve the
NA damage response.
SIRT3 is the main mitochondrial deacetylase and as such it con-
rols the activities of many metabolic enzymes in the mitochondria.
IRT3 deacetylates a long list of mitochondrial proteins acting at
everal nodes of mitochondrial metabolism, including fatty acid
xidation, glutamine metabolism, and mitochondrial ROS produc-
ion. When SIRT3 is lost or ablated, metabolic derangements occur
173], which may  be the source for the link between SIRT3 and
ancer. The first described link between SIRT3 and cancer reported
hat SIRT3KO mice spontaneously develop mammary tumors after
 years [174]. Furthermore, this study identified SIRT3 as a tumor
uppressor by showing that SIRT3 KO MEFs could be transformed
n vitro by the addition of a single oncogene, Myc or Ras [174]. A
ater study attributed the elevated level of cellular ROS seen with
oss of SIRT3 to the stabilization of HIF-1 and activation of HIF-
 glycolytic target genes, leading to altered cellular metabolism
oward glycolysis [175]. It is possible that SIRT3 deficiency leads to
 cancer permissive state by coordinating a shift in metabolism to
 Warburg phenotype.
Cancer cells also rely heavily on the metabolism of glutamine as
 nitrogen source for protein and nucleotide synthesis necessary for
roliferation [28]. SIRT4 was previously found to inhibit the activity
f glutamate dehydrogenase (GDH) activity by ADP-ribosylation.
ore recently, one study showed that genotoxic stress causes an
nduction of SIRT4 expression leading to a repression of glutamine
etabolism [176]. SIRT4 KO MEFs had higher glutamine uptake in
esponse to UV damage and increased glutamine-dependent pro-
iferation compared to wild type cells. Finally, SIRT4KO mice had
ncreased incidence of various types of cancer, particularly lung
ancer compared to wild type mice [176].
Finally, SIRT6 controls cancer metabolism and SIRT6 ablation
ctivates aerobic glycolysis and leads to oncogenesis, in the absence
f oncogene activation [177]. This study showed that when aero-
ic glycolysis was inhibited by inhibition of PDK1, an inhibitor of
yruvate dehydrogenase (PDH), the SIRT6 deficient cells failed to
orm tumors, showing a reliance on glycolytic metabolism of glu-
ose. Further, SIRT6 expression is also low in pancreatic, colon, and
iver cancers in humans [177,178]. Overall, it seems as though SIRT6
uppresses cancer growth by regulating aerobic glycolysis and that
 mutator phenotype is not required for SIRT6-dependent tumor
ormation.
Collectively, these studies show that the loss of an individual sir-
uin can promote oncogenesis by creating a state that is favorable to
ancer cell formation or survival, such as increasing DNA damage,
nhibiting DNA repair mechanisms, or altering cellular metabolism
oward a Warburg-like phenotype. Modulating sirtuin expression
ay  be a way to alter substrate use by cancer cells and slow or
revent their growth. Many of the sirtuins are known to be regu-
ated by nutrient status, therefore it may  be beneficial to modulate
irtuin expression by diet and/or exercise. SIRT1 and SIRT3 expres-
ion are induced with calorie restriction and fasting, and SIRT3
xpression is reduced with high fat diet (HFD) feeding [179,180].
odulating sirtuin expression through diet, and possibly exercise,
ay  be useful in combination with conventional cancer therapy.
y combining chemotherapy with calorie restriction or exercise
described below), sirtuin expression may  be elevated leading to
 more normalized cellular metabolism and better control of the
ancer, possibly increasing the efficacy of the drug therapy. Along
hese lines, efforts aimed at identifying calorie restriction mimetics,
imilar in action to resveratrol, have the overall goal of increas-
ng the expression or activity of the sirtuins. However, resveratrol,
ther CR mimetics, and dietary manipulations are not selective forer Biology 35 (2015) S129–S150
a particular sirtuin and may have undesired or off-target affects,
and most importantly may  not activate the sirtuins robustly. More
investigation into the sirtuins in cancer is clearly needed, and bet-
ter ways to selectively target individual sirtuins will be key moving
forward.
7.5. One-carbon metabolism
The folate cycle in combination with the methionine cycle are
collectively referred to as the one-carbon metabolism, since car-
bon units are circulated through multiple enzymatic reactions.
The one-carbon cycle forms a critical component of the cellu-
lar metabolic network, which is linked to nearly all of the major
biosynthetic pathways. The main sources that put carbon units into
this cycle are serine and glycine biosynthetic pathways. Impor-
tantly, the fate of the carbons (i.e. outputs) of the one-carbon
cycle consist of a variety of critical metabolic pathways; for exam-
ple, some outputs include nucleotide metabolism [181], protein
translation [182], lipid metabolism [183], methylation metabolism
[121,123,184–186], protein sulfhydration, and glutathione produc-
tion. Therefore, the activity of the one-carbon cycle is important
in regulating the biosynthesis of the building blocks of a cell as
well as its epigenetic status. Furthermore, the redox state of the
cell is regulated by this cycle at two  levels: through the folate
cycle by the function of tetrahydrofolate (THF), and also through
the glutathione production via the transulfuration pathway that
mediates the levels of ROS in cells. Both of these mechanisms serve
to regulate the balance of NADPH/NADP+ levels in the cell [24].
Recently, a variety of cancers were shown to divert carbons from
glycolytic metabolism into the one-carbon cycle, providing a link
from the Warburg effect to the activity of one-carbon metabolism
[187,188].
For example, phosphoglycerate dehydrogenase (PHGDH) is
hyperactivated in a subset of cancers, resulting in over-production
of serine in these cancers [189,190]. Furthermore, the gene encod-
ing PHGDH was  shown to have undergone significant copy number
gain in some cancers and cancer cell lines, and these cell lines
were dependent on the PHGDH amplification for rapid proliferation
[191].
A second instance where one-carbon metabolism has shown
correlations with cell transformation is the metabolism and
generation of glycine. A metabolomics study on cancer cell
lines reported a strong association between glycine uptake and
catabolism with cancer cell proliferation [192]. Also another study
found that ectopic expression of glycine dehydrogenase (GLDC,
decarboxylating), phosphoserine aminotransferase (PSAT), and
serine hydroxymethyltransferase (SHMT), all enzymes important
in glycine uptake and catabolism, could induce cell growth in NIH
3T3 cells, thus conferring to these cells properties indicative of the
hallmarks of cancer [193].
Additional levels at which the one-carbon cycle and its out-
put pathways have been linked to cancer include nucleotide
metabolism, epigenetic modifications, polyamine metabolism, and
the regulation of the oxidative state of the cell. Multiple genes
involved in nucleotide metabolism cause transformation by reduc-
ing the genomic integrity [194]. Also, through the transfer of methyl
groups to proteins, DNA, and RNA, S-adenosyl methionine regulates
protein activity as well as epigenetic marks on DNA and proteins in
cells which are all broadly implicated in cancer.
Targeting one-carbon metabolism using folate antagonists has
long been used as a major class of cancer therapeutic agents
[195]. Historically, aminopterin was the first one of such drugs,
and methotrexate and pemetrexed are still being used as common
chemotherapeutic agents in a variety of cancers acting to inhibit
di- and tetrahydrofolate reductase activities, thereby disrupting the
one-carbon cycle. In addition to this class of compounds, another
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ajor group of chemotherapeutic agents linked to the one car-
on cycle are inhibitors of nucleotide metabolism. These include
-fluorouracil (5-FU) and gemcitabine [196].
Furthermore, several novel anti-cancer drugs that are currently
eing tested in clinical trials also target specific components of the
ne carbon cycle. These agents mostly target the epigenetic state of
he cancer cells through inhibiting SAM or DNA methyltransferases
r polyamine synthesis [197]. Difluromethylornithine (DFMO),
ethylglyoxal bis(guanylhydrazone) (MGBG), and an inhibitor of S-
denosylmethionine decarboxylase called SAM486A are examples
f such agents.
One carbon metabolism consists of enzymes that are in principle
ruggable [198]. Therefore, several promising drug targets include
HGDH, PSAT, PSPH, GCAT, GLDC, and glycine N-methyltransferase
GNMT). A recent study has shown that reduction in serine and
lycine intake in diet can significantly reduce cancer cell prolifera-
ion in mice, suggesting that one carbon metabolism can potentially
e targeted through dietary adjustments [199]. Finally, due to the
revalence of anti-metabolite chemotherapeutic agents that are
omehow involved with the one carbon cycle, expression levels of
ome of the components of this pathway could potentially be used
s biomarkers for drug selection and outcome prediction in several
ypes of cancers [200,201].
.6. Oncometabolites
Isocitrate dehydrogenases (IDH1 and IDH2) are frequently
utated in several cancer types, including glioma, acute myeloid
eukemia, and chondrosarcoma [202–204], resulting in signifi-
ant changes to the epigenetic landscape in cancers harboring
hese mutations [120,141,205,206]. The products of wild type
DH1 and IDH2 enzymes, NADPH and -KG, play broad functions
n regulating cellular metabolism. The mutant IDH proteins lose
heir wild type function and instead convert -KG into (R)-2-
ydroxyglutarate [(R)-2HG], a structural analog of -KG [207]. IDH
utant cancer cells can accumulate millimolar levels of this nor-
ally undetectable metabolite [207,208]. Recently, mouse models
ith altered IDH2 activity have shown the capacity of IDH muta-
ions to facilitate malignant tumor development and maintenance
209,210].
(R)-2HG is thought to act by competitively inhibiting certain
nzymes that require -KG as a cofactor, including Jumonji-C
omain histone demethylases (JHDMs) and TET proteins, which are
mplicated in DNA demethylation [211,212]. IDH mutant tumors
isplay a hypermethylation signature, associated with a block in
ellular differentiation [120,141,211]. A similar hypermethylation
ignature is associated with IDH mutations and TET2 mutations,
hich occur in a mutually exclusive manner in AML, indicating that
hese mutations likely target the same pathway [141]. Moreover,
ither treatment with (R)-2HG or silencing of TET2 was sufficient to
romote growth factor-independent growth of TF-1 leukemia cells
213]. However, the epigenetic alterations mediated by (R)-2HG
ay not fully explain its cancer promoting effects, since (S)-2HG,
hich is not produced by mutant IDH but serves as an even more
otent inhibitor of TET2 than (R)-2HG, fails to transform TF-1 cells.
ne possible explanation is that (R)-2HG, but not (S)-2HG, can act as
n agonist for EGLN prolyl hydroxylases, which promote hypoxia-
nducible factor (HIF) degradation; hence regulation of HIF proteins
ay  also be a part of the malignant tumor-promoting activity of
R)-2HG [213,214]. Indeed, EGLN1 silencing impaired the ability of
DH1 R132H to transform TF-1 cells.
2HG has emerged as a useful diagnostic marker for patients with
DH mutant tumors. Patients with IDH mutant AML  exhibit elevated
erum 2HG levels, and those with the highest levels of 2HG had
horter overall survival [215]. Moreover, 2HG can be detected non-
nvasively by magnetic resonance spectroscopy in patients wither Biology 35 (2015) S129–S150 S139
IDH mutant glioma [216]. Substantial interest has also arisen in
therapeutic targeting of mutant IDH enzymes, as a cancer-specific
metabolic alteration. Inhibitors to mutant IDH1 and IDH2 were
recently reported. For example, an IDH2/R140Q inhibitor promoted
the differentiation of leukemia cells containing that mutation [217].
An IDH1/R132H inhibitor likewise promoted differentiation and
reduced histone methylation in glioma cells. Growth of glioma
xenografts was  also impaired. Notably, the tumor growth inhibitory
effects of the drug were observed at lower doses than were required
to stimulate histone demethylation and differentiation, further
suggesting that additional mechanisms may  contribute to mutant
IDH-mediated malignant tumor growth [218].
In addition to (R)-2HG, succinate and fumarate also have the
potential to act as oncometabolites. In specific cancer types, loss-
of-function fumarate hydratase (FH) and succinate dehydrogenase
(SDH) mutations are observed, resulting in build-up of fumarate
and succinate, respectively. Similar to 2HG, fumarate and succinate
can competitively inhibit -KG-dependent dioxygenases. As such,
succinate has been known for several years to promote HIF1 stabi-
lization via inhibition of prolyl hydroxylases [219]. More recently, it
has been identified that succinate and fumarate also inhibit histone
demethylases and TET proteins [220]. Both SDH mutant gastroin-
testinal stromal tumors and paraganglioma were shown to exhibit
a hypermethylation phenotype [221,222].
7.7. Lactate
Lactate is made from pyruvate by the enzyme lactate dehydro-
genase (LDH) during normal cellular metabolism (Fig. 1). Cancer
cells produce high levels of lactate, as described above. More
recently, a new role for lactate has been described wherein some
cancer cells use lactate to enable proliferation. For example, in
a cancer microenvironment, excess lactate is secreted and con-
tributes to an extracellular environment that promotes cancer
progression [223]. Thus, lactate, which was previously considered
a waste product of cancer cells, has now been identified as a key
metabolite that plays a direct role in promoting cellular growth.
The concept of the role of lactate as a signal or as a fuel in cancer is
often called the “reverse Warburg effect” [224].
Lactate levels are governed by a number of factors, including dif-
ferential expression of LDH isoforms, the lactate monocarboxylate
transporter (MCT) levels, and oxidative capacity of tissues. LDH is
the primary enzyme catalyzing lactate turnover, which intercon-
verts pyruvate and lactate, with concomitant interconversion of
NADH and NAD+, respectively. LDH is involved in the metabolism
of both glucose and glutamine carbon, as well as in determining
malignant tumor pH and the activity of the TCA cycle [225]. LDH is
classified into five different subtypes (LDH1–5), which structurally
conform into homo- or hetero-tetramers of M protein subunits
encoded by LDH isoform A (LDHA) and H protein subunits encoded
by LDH isoform B (LDHB) genes. These subtypes vary based of tissue
distribution. For example, in normal tissue, LDH1 has high expres-
sion in the brain, heart, and kidney; LDH5 is found in glycolytic
tissues, such as liver or skeletal muscle [226].
Recently, LDHA was shown to be required for the maintenance
and progression of many cancers [227–230], but the mechanisms
by which LDHA facilitates cancer progression remain poorly under-
stood [231]. Given the correlation between LDHA levels and cancer
outcomes, LDHA has attracted attention as a cancer target. Reduc-
ing LDHA levels (by shRNA) in cells leads to decreased proliferation
and suppressed oncogenicity [227]. Furthermore, inhibition of
LDHA pharmacologically or by siRNA reduces ATP levels and results
in cellular death [228]. A follow-up study examining the com-
bination treatment of the LDHA inhibitor FX11 and the NAD+
synthesis inhibitor FK866 resulted in lymphoma regression in a
xenograft model [228]. Another study found that LDHA plays a role
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n chemoresistance in breast cancer [232]. Specifically, paclitaxel-
esistant breast cancer cells have high expression and activity of
DHA compared to paclitaxel-sensitive cells. Importantly, down-
egulation of LDHA restores chemosensitivity, indicating that
actate dehydrogenase, and more broadly lactate levels, play a key
ole in cancer drug resistance.
In addition to LDH, MCTs have gained interest as therapeutic
argets for their ability to import and export lactate. This family of
ransporters moves lactate and a proton down a concentration gra-
ient, which determines the directionality of transport. Similar to
DH, different MCT  isoforms are expressed in tissue types accord-
ng to their oxidative capacity [233,234]. For example, MCT1 is high
n oxidative cell types like muscle sarcolemma [235], and increases
ith training. MCT4, on the other hand, is found in cells with high
ates of glycolysis, such as fast-twitch muscle cells. Consistent with
his idea, its expression is increased during hypoxia.
MCTs have also garnered interest as regulators of lactate
etabolism. Indeed, inhibition of MCT1, either pharmacologically
ith -cyano-4-hydroxycinnamate (CHC), or by RNA interference,
hifted metabolism from lactate consumption to glucose consump-
ion in normoxic cells. Interestingly, this also revealed a metabolic
exibility of cancer cells. Some studies have tested MCT1 inhibi-
ion in vivo. In one mouse model of lung cancer and in a xenograft
f human colorectal adenocarcinoma, CHC administration reduced
ypoxia, induced tumor necrosis, and slowed overall growth. In
nother study, CHC was able to induce anti-tumoral and anti-
ngiogenic activity in gliomas, as well as to potentiate the effect
f the alkylating agent temozolomide [236].
To conclude this section on emerging metabolic derangements
ontributing to cancer cell growth, we end with lactate – Warburg’s
riginal observation. Collectively, these studies support a model
here metabolites, like lactate, which facilitate malignant tumor
evelopment and/or survival, have the potential to be targeted
herapeutically.
. Therapeutic strategies
Metabolism is a recent addition to the hallmarks of cancer, and
he nature of these changes and their significance for the etiology of
he disease are areas of intense investigation. As in other reviews of
Hallmarks of Cancer’ in this special issue, both molecular targets
nd small molecules were evaluated as lead candidates to influ-
nce different aspects of cancer metabolism. Each of the priority
argets was outlined in the preceding sections and together are
ummarized in Table 1. These areas were chosen for their known or
merging mechanisms to contribute to dysregulated metabolism in
ancer.
A team of researchers consisting of specialists in each hallmark
rea performed an extensive literature search to determine if any
tudies had been performed addressing the effect of each molecular
arget (Table 1) on other hallmarks. The ‘Target Validation Team’
lso looked for any possible reports of effects by the identified
herapeutic approaches on other hallmarks. Given the interest in
uture research that will focus on combinatorial approaches, this
ffort was primarily aimed at highlighting any evidence of con-
rary effects in other hallmark areas. However, any potential for
omplementarity or synergy were also considered as well.
Remarkably, many targets described above as having poten-
ial to manipulate different aspects of cancer metabolism have not
een directly tested in the context of other hallmarks. Furthermore,
ompounds directed at each molecular target need to be tested for
heir influence on other hallmarks, independent of their effects on
etabolism; this is the current major gap in knowledge. We  pri-
arily attribute this to the recent resurgence in metabolic studies,
specially in the context of cancer. Indeed, less is known about ifer Biology 35 (2015) S129–S150
and how to effectively target cancer metabolism as a therapy than is
known about targeting other hallmarks of cancer. Thus, our analysis
at this time shows that prioritized targets and lead compounds that
might affect these targets need further investigation. With more
research, a broad-spectrum approach to target metabolism and to
synergize with other hallmarks of cancer could be achieved.
In the interim, based on current knowledge, we consider
from a drug development perspective the unique environment of
mitochondria, which needs to be considered to target mitochon-
drial function, and ultimately manipulate metabolism. Because of
the challenges associated with targeting mitochondria, we also
take a step back from the cellular and biochemical mechanisms
of metabolism and discuss how alterations in host metabolism
could more broadly manipulate cancer metabolism in an effica-
cious way. Together, considering cancer (direct) and host (indirect)
metabolism could uncover novel therapeutic strategies or informa-
tion that could be leveraged to target metabolism.
8.1. Strategies to target mitochondria in cancer
Traditionally, mitochondria were not thought of as a ‘Drug-
gable Target’ due to significant challenges unique to mitochondria,
including selective delivery to this organelle, specific mitochondrial
uptake within a targeted organ, and how to enhance the selective
delivery to mitochondria within cancer cells; however, recent work
is changing this view [237,238]. In part, this is due to the grow-
ing realization that mitochondrial function contributes to multiple
cellular functions, beyond energy metabolism, and these aspects
could be targeted. The development of strategies to target different
aspects of mitochondrial biology has led to the emergence of a new
field called mitochondrial pharmacology [237,238].
In mitochondrial pharmacology, development of drugs designed
to affect mitochondria require the following considerations. Fore-
most, mitochondria originate from the coordination of two
genomes, with 37 genes in the mitochondrial DNA and approx-
imately 1500 proteins being imported into the mitochondria
following their transcription and translation from nuclear genes
[239]. The expression of the two genomes is coordinated by a
number of nuclear transcription factors [240]. Targeting nuclear-
versus mitochondrial-derived proteins could be important. Fur-
thermore, the mitochondria themselves continually join and
separate through fission/fusion processes that are linked to
the turnover and degradation of damaged, defective or surplus
mitochondria [241]. Thus, one way  for drugs to alter mitochon-
drial function is through interaction with the cellular machinery
that controls overall mitochondrial biogenesis. For example, drugs
such as 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)
that interact with the AMP-activated protein kinase (AMPK) [242]
may  lead to upregulation of global mitochondrial biogenesis. Fur-
thermore, agonists for PGC1, a transcriptional co-activator that
regulates gene expression of nuclear encoded mitochondrial pro-
teins may  do the same [243]. Such strategies may  globally alter
mitochondrial nutrient oxidation or function in therapeutically
useful ways in cancer.
More direct strategies have been demonstrated by using drugs
that act on particular targets within mitochondria. For example,
dichloroacetate has been explored as an anticancer agent by block-
ing the activity of the inhibitory kinase that inactivates pyruvate
dehydrogenase, thereby enhancing mitochondrial pyruvate oxida-
tion [244]. Generally, in these examples, a drug acts on an aspect of
metabolism that is mitochondrial and the selectivity comes from
the interaction of the drug with its target, which happens to be in
the mitochondrion. However, emerging methods are available to
target compounds to mitochondria [237], and these may  have a
number of advantages. In particular, the concentration of a com-
pound within mitochondria greatly enhances the potency of the
 Canc
t
l
m
i
m
d
o
i
i
t
o
a
o
i
s
t
m
m
m
R
g
s
e
s
l
f
e
8
a
u
b
l
s
w
m
w
o
w
i
o
o
t
8
t
s
p
d
s
t
s
v
b
i
a
t
t
i
oM.D. Hirschey et al. / Seminars in
herapy, meaning far less of a compound might be required. The
ocalization of the compound within the mitochondria also mini-
izes metabolism and toxicity associated with reactions elsewhere
n the body.
An important attribute in designing targeted therapies for
itochondria is the distinct mitochondrial compartments, with
ramatically different properties. Most of energy metabolism
ccurs in the matrix and on the mitochondrial inner membrane. The
ntermembrane space has limited metabolic activity, although it is
mportant in protein import; this compartment contains many of
he proteins that are released into the cytoplasm during activation
f apoptotic pathways. The mitochondrial outer membrane is also
 key component in the regulation of apoptosis. Furthermore, many
f the complexes involved in the propagation and stabilization of
nflammatory pathways are assembled on the cytoplasmic-facing
urface of the mitochondrial outer membrane [245].
Overall, the role of mitochondria in cancer is becoming bet-
er understood, suggesting that therapies targeted to the organelle
ay  be useful [246,247]. Drugs could be designed to affect
itochondrial function directly by binding to targets within
itochondria, or indirectly by altering mitochondrial biogenesis.
ecent developments have also led to robust strategies to tar-
et bioactive compounds to mitochondria. These approaches may
electively modify mitochondrial metabolism in cancer cells to gen-
rate therapeutically beneficial outcomes, such as enhancing the
elective killing or inhibiting growth of cancer cells. While many
imitations and uncertainties with these approaches remain, modi-
ying mitochondrial function could become a therapeutically useful
xtension of current cancer treatments.
.2. Strategies to target metabolic interactions between cancer
nd host
As an alternative strategy, cancer metabolism might be manip-
lated specifically through host metabolism. This rationale is
ased on the concept that pharmacological mimetics of weight
oss, calorie restriction, and/or targeting the associated hormonal
ystems and intracellular signaling pathways are emerging path-
ays for novel cancer therapeutics. Indeed, one of the possible
echanisms underlying known efficacy of fasting, CR, exercise, or
eight loss on cancer could be multi-faceted, synergistic effects
f these “treatments”. Thus, manipulating metabolism in these
ays could be a successful therapeutic strategy. Further study-
ng physiological approaches that influence a broad-spectrum
f targets and/or hallmarks could inform more effective design
f pharmacological approaches aimed at a broad-spectrum of
argets.
.3. Calorie restriction, fasting, and cancer
Calorie restriction (CR), usually referring to a 20–40% reduc-
ion in the daily intake of calories without malnutrition has been
hown to extend lifespan and healthspan in multiple species, in
art by delaying or preventing the occurrence of many age-related
isorders including cancer [248–250]. CR has been also demon-
trated to reduce the frequency of spontaneous and inducible
umors in mice and primates [251–256]. However, CR induces
ignificant weight loss, which has limited its efficacy and has pre-
ented its wide-spread clinical use. In some studies, CR delayed
ut did not stop tumor growth progression, and some tumors
ncluding those carrying a mutation in oncogenes such as PI3K
nd phosphatase and tensin homolog (PTEN) have been shown
o be resistant to CR [257]. In addition, CR would be predicted
o be incompatible with the treatment of most cancer patients
ncluding those malnourished or at risk for severe weight loss,
r affected by immunosuppression or cachexia [258]. In fact,er Biology 35 (2015) S129–S150 S141
long-term CR can impair immune functions and delay wound
healing repair [259,260]. Thus, while CR might not be compat-
ible with cancer therapy in humans, several lessons could be
learned from the molecular pathways activated by CR and/or CR
mimetics.
More recently, periodic fasting has emerged as a viable strategy
to protect normal cells from toxicity associated with chemother-
apy, while sensitizing cancer cells to treatment. Remarkably, fasting
protects normal cells from oxidants, common chemotherapeutic
agents, and radiotherapy in several in vitro and in vivo models
[261–263]. Specifically, glucose and serum starvation in vitro and
a 48–72 h food deprivation (short-term starvation or STS) in mice
activated several stress–response pathways that conferred resis-
tance to oxidative stress induced by chemotherapy. The latter effect
was termed “differential stress resistance” (DSR) [264], and is based
on the concept that normal cells can adapt to stressors but not can-
cer cells [265]. The mechanisms responsible of starvation-induced
DSR in mammals include reduced circulating insulin-like growth
factor 1 (IGF-1) levels and possible down-regulation of growth
pathways [264]. In addition, in normal mammalian cells, starva-
tion has been demonstrated to induce AMPK which stabilized p53
and p21 thereby resulting in cell proliferation arrest [262].
In model organisms, including bacteria and yeast, the switch
from nutrient rich media to water or buffer extends longevity
and also increases resistance to a variety of toxins, including ROS
[261,266,267]. In yeast cells, the molecular mechanisms respon-
sible for fasting-mediated protection involve the reduced activity
of components of the glucose-response Ras/cAMP/PKA pathway
and of the amino acids response Tor/S6K pathway [266,268,269].
Similarly, fasting increases resistance to oxidative stress and pro-
longs life-span in model organisms, such as worms and flies, by
down-regulating analogous nutrient-sensing pathways such as
(PI3K/AKT/TOR) [270,271].
Cancer cells are characterized by the presence of oncogenic
mutations in the same growth signaling pathways including IGF1
receptor, PI3K, PTEN, Ras, and PKA that prevent the activation of
protective systems in response to starvation (DSR) [1]. In addition
to the absence of a stress resistant response to starvation, the set
of mutations and chromosomal rearrangements prevent malignant
cells from being able to adapt to a wide variety of conditions but
particularly to those that involve broad and extreme changes such
as starvation. Thus, “differential stress sensitization” (DSS) takes
advantage of the fact that most mutations reduce the ability of
cells to withstand changing environments. In one study, 48–60 h
of fasting retarded malignant tumor growth, similar to chemother-
apy, and acted in synergy with chemotherapeutic drugs in killing
a wide variety of cancer cells [264]. In mouse models for breast
cancer, neuroblastoma, mesothelioma, and lung carcinoma, the
combination of fasting and chemotherapy promoted 20–60% can-
cer free survival, whereas neither one of them alone resulted in any
cancer free survival [262,264]. Investigation of the molecular mech-
anisms underlying the STS-mediated biological effects indicate that
breast cancer cells attempt to compensate for the nutrient defi-
ciency caused by fasting by hyperactivating the AKT and mTOR/S6K
pathways, increasing translation and, as a result, consuming even
more energy and causing oxidation-dependent cell death [264]. A
recent study in lung cancer cells, instead showed that starvation
activated ATM/Chk2/p53 which sensitized cells to cisplatin treat-
ment [262]. Many different mechanisms are likely responsible for
the effects of fasting in the sensitization of different types of cancer
cells. However, some of these mechanisms could to be shared by
all cancer cell types.The side effects caused by chemotherapeutic toxicity to nor-
mal  cells and tissues are a major limitation of these agents.
Consequently, these toxicities can limit chemotherapeutic dose
intensity and compromise its overall efficacy. The need to maintain
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hemotherapeutic doses within this treatment range could be con-
ributing to the survival of a sufficient number of cancer cells and
ead to recurrence. Thus, reducing toxicity of chemotherapeutics by
rotection of normal cells and tissues, in combination with sensi-
izing of cancer cells, during fasting represents a promising strategy
o enhance current treatments.
The safety of this intervention has been demonstrated in stud-
es of a large cohort of patients affected by rheumatoid arthritis,
ho did not reveal any major adverse effect and presented clinical
mprovement after undergoing prolonged fasting [272]. Similarly,
ypertensive patients, who fasted with only water for 10–11 days,
howed normalization of systolic blood pressure values and no
ajor side effects [273]. These studies provide a proof-of-principle
or fasting in human studies.
The first clinical test of fasting in patients during chemotherapy
as reported in a study where 10 patients affected by differ-
nt malignancies voluntarily fasted 48–140 h prior to and during
hemotherapy. This study reported that fasting may  reduce the
ide-effects induced by chemotherapeutic toxicity in humans [274].
otably, these patients receiving different chemotherapeutic drugs
n combination with fasting reported hunger and light-headedness
s significant side-effects, and reported fewer toxicities associated
ith chemotherapy, including weakness, fatigue, and gastrointesti-
al distress [274]. Importantly, fasting did not appear to interfere
ith chemotherapeutic efficacy [274].
The combination of fasting with chemotherapy has gained clin-
cal interest as a therapeutic approach for cancer patients [275].
everal clinical trials are now exploring fasting as a way to reduce
he toxicity of chemotherapy and increase its efficacy in humans
e.g. ClinicalTrials.gov numbers, NCT00757094, NCT00936364,
CT01175837, NCT01304251). Taken together, fasting is a promis-
ng therapeutic strategy for cancer patients, with the potential to
e useful in combination with several chemotherapeutic drugs and
cross many cancer types. Future studies will determine whether
asting may  potentiate the efficacy of non-toxic cancer therapies,
ncluding antibody- or immune-based strategies.
.4. Exercise and cancer
Growing evidence shows that chronic exercise reduces the
isk of certain forms of malignancies (i.e., prevention) compared
ith sedentary lifestyles [276,277]. In addition, emerging evidence
ndicates that chronic exercise may  also be inversely correlated
ith cancer-recurrence as well as cancer-specific mortality (i.e.,
rognosis) [278,279]. While data are not currently available from
andomized trials testing the role of exercise in either prevention
r prognosis, the combination of the unique metabolic features
f malignant tumor cells and exercise-induced perturbations in
hole-body and intracellular metabolic substrate use suggests that
xercise might directly influence cancer prognosis and survival
279,280].
Investigation into the effects of metabolic perturbations in a
hemically induced rat model of breast cancer showed that both CR
nd voluntary wheel running reduced tumor incidence and burden
281]. This reduction occurred in conjunction with reductions in
irculating plasma levels of metabolic factors such as IGF-1, insulin,
eptin, and increased plasma levels of IGF-binding protein 3 (IGFBP-
) and adiponectin. Further studies using the same breast cancer
odel showed that CR combined with voluntary wheel running
nhibited tumor growth, and was associated with downregulation
f mTOR-related targets including pAkt [282]. Plasma insulin and
eptin were strongly correlated with intratumoral pAkt levels. In
ontrast, another study found tumor growth was similar between
edentary control groups and voluntary wheel running in animals
rthotopically implanted with human breast cancer or prostateer Biology 35 (2015) S129–S150
cancer [283,284]. More work needs to be done in this area to deter-
mine if and how exercise affects tumor growth in these models.
Several studies in humans have investigated the effects of
structured exercise training interventions on changes in metabolic
parameters in subjects at-risk or with a confirmed diagnosis of can-
cer. For example, the Physical Activity for Total Health (PATH) Study
found that structured moderate-intensity exercise training had no
effect on circulating levels of IGF-1, IGFBP-3, or the ratio [285].
However, in these at-risk patients, training was associated with
improvements in insulin and leptin levels [286]. In patients diag-
nosed with cancer, several studies have found that exercise training
is associated with favorable changes in circulating levels of these
same metabolic growth factors. For example, moderate intensity
aerobic training (defined as 60–75% of baseline VO2peak, 3 times
per week, for 30–45 min  per session, over 15 weeks) lead to alter-
ations in IGF-1, IGFBP-3, and the IGF-1:IGFBP-3 ratio compared to
a sedentary controls [287]. This is consistent with larger studies
on aerobic exercise and resistance training in patients with breast
cancer [288–290]. In another study, sedentary early-stage breast
cancer patients were randomly assigned to a home-based aerobic
and resistance exercise program for 16 weeks or a control group
[291]. Another study using aerobic exercise found a trend toward
decreased fasting insulin [292].
Indeed, the potential of exercise to alter host–tumor metabolic
interactions may  not only cause a shift toward a less aggressive
phenotype but could also alter sensitivity to anticancer therapies.
Based on current knowledge, it is difficult to predict the complex
and multifaceted interaction between the host, exercise, tumor,
and antineoplastic index of current therapeutics. However, exer-
cise may  affect tumor cell sensitivity in at least two ways. First, solid
tumors have an abnormal vascular system that impairs effective
oxygen and drug transport [293,294], which is associated with ther-
apeutic resistance [293,295]. In contrast, exercise leads to favorable
vascular adaptations in preclinical models of cardiac and hindlimb
ischemia, as well as improvements in peripheral vascular function
[296–300]. Similarly, tumors from exercised mice had significantly
increased intratumoral perfusion and vascularization (i.e. physi-
ologic angiogenesis) in orthotopic models of breast and prostate
cancer [283,284]. One study recently reported that the combi-
nation of exercise (voluntary wheel running) and chemotherapy
(cyclophosphamide) was  associated with significantly prolonged
tumor growth delay compared with chemotherapy alone in a
mouse model of murine breast cancer. Although the molecular
mechanisms remain to be elucidated, hypoxia is intricately linked
with tumor metabolism and exercise may  effect vascularization
and chemosensitivity. Second, as described above, short-term calo-
rie restriction and/or fasting induces a stress response adaptation
in normal cells that provides protection against oxidative injury
from chemotherapy [261,264]. Importantly, cancer cells have an
impaired ability to respond to CR-induced stress, and may increase
the therapeutic index. Exercise is also a potent form of both host
and intracellular stress that may  also confer similar effects to caloric
restriction.
The data from these early studies, coupled with the power-
ful influence of exercise on metabolic homeostasis, suggest that
more research in this area is needed. Specifically, investigations
that adopt a translational approach are required to determine how
exercise influences metabolic milieu in conjunction with biomark-
ers of tumor metabolic phenotypes using tissue and imaging
modalities. Overall, careful elucidation of the molecular mecha-
nisms by which exercise influences cancer metabolism could lead
to rational pharmacologic agents to optimize clinical outcomes.
Indeed, several lessons can be learned from interactions between
cancer and fasting, cancer and CR, as well as cancer and exer-
cise. Such research has the potential to provide new therapeutic
opportunities.
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.5. Obesity and cancer
At the other end of the metabolic spectrum, the obese phe-
otype is characterized by profound metabolic dysregulation,
nd can especially disrupt the endocrine system [301–304]. The
007 World Cancer Research Fund/American Institute for Can-
er Research (WCRF/AICR) report and subsequent epidemiological
tudies showed that obesity was associated with a number of
ifferent cancers, including colorectal, kidney, liver/gall bladder,
ancreatic, esophageal, stomach, prostate, postmenopausal breast,
ndometrial, uterine and ovarian cancers [305]. Factors associated
ith weight gain and obesity, excess calorie intake/or low energy
xpenditure, were concluded to increase obesity-related cancers,
hile those protecting against weight gain also protected against
eveloping cancers [305]. Recent statistical modeling of data from
he American Cancer Society cohort, which provided early evidence
f obesity–cancer links [306], estimated that 20% of cancer deaths
re attributable to being overweight or obese [307]. Consequently,
besity and obesity-associated morbidities, such as diabetes, have
een intensively investigated to determine the signaling pathways
nvolved that lead to increased carcinogenesis [308–310] and if
nti-obesogenic therapies are effective for cancer treatment and/or
revention.
Several manifestations of the obese phenotype overlap with
ancer phenotypes and provide insights into approaches for
etabolic modulation and possible strategies for cancer therapy.
n particular, both cancer and obesity are associated with activa-
ion of cellular signaling pathways. Therefore, strategies to prevent
ynthesis or secretion of the signaling molecules dysregulated
y obesity, or alternatively hindering their interaction with tar-
et receptors, may  be a useful strategy for cancer preventative
herapies. For example, therapeutic targeting of the intracellu-
ar pathways, such as JAK/STAT and PI3K/Akt/mTOR, which are
ften activated in both cancer and obesity, presents opportu-
ities to intervene in carcinogenesis. Additionally, cancer and
besity activate anabolic processes, and small molecules that dis-
upt macromolecule biosynthesis, such as metformin and orlistat,
wo drugs that lower glucose and inhibit cellular FA synthesis,
espectively, might have the ability to restore homeostatic control
nd cellular defense systems with potential to impact cancer cells
ithin the body [311,312]. Indeed, metformin has received signifi-
ant attention recently as a possible chemotherapeutic; for a recent
eview, see [313]. Finally, weight loss and reduced calorie con-
umption have been demonstrated to normalize altered adipokine
rofiles, reduce oxidative stress, and lower growth factors link-
ng obesity and cancer, suggesting that synergistic manipulation of
hese pathways along with metabolism holds therapeutic promise.
In conclusion, most molecular targets identified above as hav-
ng potential to manipulate different aspects of cancer metabolism
ave not been directly tested in the context of other hallmarks.
hus, our analysis shows that more work needs to be done on can-
er metabolism to identify targets or compounds that could have
ynergistic effects with other hallmarks against cancer. However,
he emerging efficacy of physiological strategies to manipulate host
etabolism, such as fasting/CR, exercise, or weight loss could be
ttributed, in part, to their ability to influence cancer metabolism
s well as several other hallmarks of cancer. Future studies in this
rea will determine if and how dysregulated metabolism in cancer
an be targeted directly or indirectly through host metabolism.
. TradeoffsThe recognition that cancer cells have altered metabolic
athways from their normal counterparts has opened a new oppor-
unity to treat cancer [314]. Identification of altered metabolicer Biology 35 (2015) S129–S150 S143
enzymes and regulation of metabolism through oncogenic signals
may  render cancer cells highly dependent on specific pathways and
metabolic programs. Mutations in some enzymes can force alter-
nate metabolic pathways or oncogenes can drive specific metabolic
programs while limiting alternatives. Targeting these pathways,
therefore, may  directly lead to cancer cell death or may  pro-
vide opportunities to generate synthetic lethality. The challenge
in targeting cancer metabolism, however, is that even if cancer
cells are highly dependent on specific metabolic pathways, nor-
mal  cells use these same pathways. To what extent cancer cells
and normal cells differentially rely on specific metabolic pathways
will be crucial to determine the therapeutic window of any treat-
ment [126].
A key benefit of aerobic glycolysis is the generation of metabolic
intermediates for biosynthesis and cell growth [24]. Of  course, nor-
mal  cells also undergo rapid cell growth in development and upon
stimulation. It is now evident that oncogenic signals can mimic
normal growth factor signaling mechanisms. That these signals
are sufficient to directly promote aerobic glycolysis has implied
that normal cells also utilize these same metabolic pathways.
Indeed lymphocytes transition from a quiescent metabolic state
that is characterized by oxidative metabolism to one that is highly
glycolytic upon stimulation with antigen in appropriate inflam-
matory conditions. Key pathways to drive this transition include
the PI3K/Akt/mTORC1 and cMyc pathways – each of which are
well established to drive aerobic glycolysis in cancer, as described
above. The purpose of this glycolytic phenotype in lymphocytes is,
as in cancer cells, to drive cellular growth [315]. In addition, how-
ever, aerobic glycolysis may  also have a signaling role to promote
expression of inflammatory cytokines.
Interestingly, not all activated lymphocytes use aerobic gly-
colysis. Depending on the cytokine environment, some CD4
lymphocytes develop into inflammatory effectors while others
develop into suppressive regulatory T cells (Treg). The signaling
pathways that drive these different CD4 T cell fates are also key
metabolic regulators, and mTORC1 is essential to develop effec-
tor T cells but represses Treg [316]. Accordingly, the metabolism
of these subsets differs. Effector T cells, like cancer cells with
activated mTORC1, are highly glycolytic [317,318]. Treg, however,
have low mTORC1 and instead have high levels of activity in the
tumor-suppressive AMPK pathway, a key inhibitor of mTORC1
and driver of oxidative metabolic pathways. Rather than favor
aerobic glycolysis, therefore, Treg utilize lipid oxidation as a pri-
mary metabolic pathway [317]. Similarly, memory T cells that
return to quiescence following an immune response revert from
the glycolytic phenotype of effector T cells to lipid oxidative
metabolism [319]. Suppressing lymphocyte glycolysis and promot-
ing oxidative metabolism, therefore, inhibits the primary effector
response but can enhance the generation and survival of memory
T cells [320].
The metabolic implications of these distinct metabolic transi-
tions of cells moving from quiescence to proliferation are manifold
and go well beyond fundamental aspects of immunology. Firstly,
lymphocytes are not unique in these transitions. Rather, it appears
to be a general feature of the transition from quiescence to prolif-
eration that cells undergo a metabolic reprogramming. Endothelial
cells also undergo metabolic reprogramming [321], as do smooth
muscle cells [322] and a variety of other cell types. Second, lympho-
cytes in the tumor environment may  have difficulty competing for
nutrients such as glucose. This nutrient limitation, in turn, would
suppress effector lymphocytes that may  play roles in anti-tumor
immunity while at the same time promoting the development and
activity of Treg that can maintain malignant tumors. Thirdly, efforts
to target metabolism in cancer metabolism-directed therapies may
have inadvertent effects to suppress normal cell proliferation. In
the case of the immune system, blocking aerobic glycolysis can
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uppress the immune system [318,323]. While this strategy could
otentially be helpful to relieve inflammatory diseases, targeting
ancer metabolism could have a tradeoff of immune suppression.
n this setting, immune suppression may  increase susceptibility to
nfection, and inhibit the potential benefit of an anti-tumor immune
esponse.
A key question now is not only to discover how cancer
etabolism itself is programmed and functions to advance can-
er, but also to understand the metabolism of normal proliferating
ells. The similarities may  be useful to exploit new developments
n cancer metabolism to target cells in other settings. In particular,
nti-inflammatory treatments may  become evident from cancer
etabolism drugs. Differences in the metabolic programs of nor-
al  and cancer cells will also be highly useful, as these distinctions
ill provide directions to target cancer metabolism, while spar-
ng other highly proliferative cells. In some cancers, mutations will
ake it clear how to selectively target cancer metabolism. For most
ases, however, it will be important to target cancer metabolism,
hile maintaining metabolic pathways regulating normal cellular
unction. This ongoing challenge will be critical for establishing the
herapeutic window for cancer metabolism treatments as well as
pening new opportunities to understand normal biology.
0. Conclusion and future perspectives
The energy requirements of cancer cells vary greatly from those
f quiescent or terminally differentiated cells. Mammalian cells
equire external cues from growth factors to take up nutrients
rom their surroundings and in the absence of these signals they
re programmed to die by apoptosis [324]. Cells must compete
or limiting amounts of growth factors that direct nutrient uptake
n order to survive. Under these conditions it is advantageous to
aximize energy production from nutrients such as glucose, fatty
cids and amino acids. This is accomplished by complete oxida-
ion of nutrients to carbon dioxide (CO2) and efficient coupling of
TP production though oxidative phosphorylation by the electron
ransport chain.
In contrast, cancer cells are characterized by growth factor-
ndependent nutrient uptake, apoptotic evasion, and uncontrolled
rowth and proliferation [1]. The metabolic profile of cancer
ells reflect these changes with increased nutrient uptake sup-
lying the raw materials to synthesize the lipids, nucleotides,
nd proteins necessary for cell growth and proliferation [325].
he metabolic reprogramming which occurs during oncogenesis
s similar to that which occurs in other cells transitioning from a
uiescent to proliferative state such as induced pluripotent stem
ells, embryonic stem cells and immune cells [326,327]. This pro-
ess involves a dramatic reworking of intermediary metabolism
rom that of a catabolic to an anabolic state. A key feature of
his transition is a shift away from oxidative metabolism toward
lycolytic metabolism, the net effect of which is to provide addi-
ional biosynthetic precursors for macromolecule synthesis [24].
ncreased glycolytic intermediates are used to generate nucleo-
ides, amino acids and reducing equivalents in the form of NADPH.
dditionally, while levels of oxidative metabolism may  be reduced,
unctional mitochondria are essential to cancer cell survival. In can-
er cells, mitochondria function not only in energy production but
lso in modulation of redox status, generation of ROS, maintenance
f calcium homeostasis, inhibition of apoptosis, and contribute
iosynthetic precursors to fuel macromolecule synthesis [246].
An important question that remains about the metabolic repro-
ramming which occurs in cancer is whether it is a driving force
r a secondary effect of oncogenic mutations. Until recently, it
as believed that metabolic reprogramming occurred secondarily
o mutations in oncogenes or tumor suppressors that activateer Biology 35 (2015) S129–S150
proliferation and survival signals [1]. However, a number of recent
findings highlight the importance of metabolic reprogramming in
driving oncogenesis (see Oncometabolites section), which provide
strong evidence that altered metabolism is a key event that is
selected for early in the oncogenic process.
Metabolic reprogramming in cancer cells is characterized
by altered expression, mutation, post-translational modification,
and/or changes in enzyme isoform expression. Regardless of the
stage of oncogenesis during which metabolic reprogramming
occurs, these unique changes could be specifically targeted to treat
cancer. For these strategies to be useful, the metabolic phenotypes
of several cancer types will have to be determined; techniques
to do so are being developed and becoming more common [328].
Once the metabolic phenotype of a cancer is known, therapies can
indirectly target upstream regulatory pathways, or directly target
aberrant biosynthetic, anabolic pathways. Importantly, many can-
cers become resistant to radiotherapies and chemotherapy because
of their altered metabolism [329]. Thus, a targeted therapy that
serves to revert cancer cell metabolism back to a more catabolic
state may  re-sensitize a tumor to other therapies.
Much additional work is required to make targeted metabolic
cancer therapies a reality. Several recent analyses, ranging from
biochemical to omic-level, have greatly increased our under-
standing of cancer metabolism. However, these techniques are
sometimes limited to use in cell culture systems that do not account
for contributions from the tumor microenvironment, the immune
system, or all hallmarks of cancer. Thus, future work will be directed
at measured alterations in metabolism directly in the context of
other hallmarks. Together, targeting metabolism specifically or
synergistically holds the potential for effectively treating a variety
of cancers.
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